Related Experiment Videos
Coronary angioplasty in the patient with acute myocardial infarction
C Landau1, D B Glamann, J E Willard
1Department of Internal Medicine (Cardiovascular Division), University of Texas Southwestern Medical Center, Dallas 75235-9041.
Insights
Percutaneous transluminal coronary angioplasty (PTCA) is a viable option for acute myocardial infarction, especially in cases of cardiogenic shock. However, routine PTCA after successful thrombolysis without ischemia offers no survival benefit and increases risks.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Acute myocardial infarction (AMI) management involves reperfusion strategies.
- Percutaneous transluminal coronary angioplasty (PTCA) and thrombolytic therapy are primary reperfusion methods.
- The role of PTCA in different AMI scenarios requires clarification.
Purpose of the Study:
- To review prospective, randomized studies on the use of PTCA in acute myocardial infarction.
- To evaluate PTCA's efficacy as primary therapy, rescue therapy, and post-thrombolysis intervention.
- To assess the impact of PTCA on left ventricular function and survival.
Main Methods:
- Systematic review of prospective, randomized trials.
- Analysis of studies comparing PTCA with thrombolytic therapy.
- Evaluation of PTCA's role in primary, rescue, and post-thrombolysis settings.
Main Results:
- Primary PTCA is a reasonable alternative to thrombolysis for evolving Q-wave myocardial infarction.
- PTCA is the preferred treatment for AMI with cardiogenic shock.
- Post-thrombolysis PTCA without ischemia provides no benefit to left ventricular function or survival.
- Routine post-thrombolysis PTCA increases risks of bleeding, transfusions, and bypass surgery.
Conclusions:
- PTCA is a valuable tool in specific acute myocardial infarction scenarios, including primary intervention and cardiogenic shock.
- Routine use of PTCA after successful thrombolysis without evidence of ongoing ischemia is not recommended.
- Careful patient selection is crucial to optimize outcomes and minimize risks associated with PTCA in AMI.
Abstract:
In patients with acute myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) may be used (1) to restore antegrade flow in the infarct artery (so called "primary" PTCA) instead of thrombolytic therapy, (2) to establish antegrade coronary flow after unsuccessful thrombolytic therapy (so called "rescue" or "salvage" PTCA), and (3) to reduce the residual infarct artery stenosis after successful thrombolysis. This review examines the prospective, randomized studies that have addressed the use of PTCA for each of these purposes. In selected circumstances, PTCA is a reasonable alternative to thrombolytic therapy in patients with evolving or recent Q-wave myocardial infarction. In those patients with acute myocardial infarction complicated by cardiogenic shock, PTCA may be the preferred treatment. After thrombolytic therapy, the use of PTCA in the absence of spontaneous or provocable ischemia offers no benefit with regard to left ventricular function or survival. In this circumstance, its use is associated with an excessive risk of bleeding, transfusions, and emergent coronary artery bypass surgery when performed within hours of infarction.